Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Wakefield

Showing results (631-640 of 661) with videos related to

Pageof 67
Sort By:
Nature Communications|May 28, 2020
CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancerElaine Sanij, Katherine M Hannan, Jiachen Xuan, et al.
American Journal of Hypertension|November 16, 2019
Self-monitoring of Blood Pressure in Patients With Hypertension-Related Multi-morbidity: Systematic Review and Individual Patient Data Meta-analysisJ P Sheppard, K L Tucker, W J Davison, et al.
Plos Medicine|September 20, 2017
Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysisKatherine L Tucker, James P Sheppard, Richard Stevens, et al.
Genome Biology|January 22, 2025
MaveDB 2024: a curated community database with over seven million variant effects from multiplexed functional assaysAlan F Rubin, Jeremy Stone, Aisha Haley Bianchi, et al.
Nature Communications|September 30, 2018
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaOlga Kondrashova, Monique Topp, Ksenija Nesic, et al.
The Journal of Rheumatology|March 4, 2014
Updating the OMERACT filter: implications for imaging and soluble biomarkersMaria-Antonietta D'Agostino, Maarten Boers, John Kirwan, et al.
British Journal of Cancer|July 8, 2026
Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trialKatrin M Sjoquist, Alexander Dobrovic, Kristy P Robledo, et al.
The Lancet. Rheumatology|January 22, 2024
Development and validation of an OMERACT ultrasound scoring system for the extent of calcium pyrophosphate crystal deposition at the joint level and patient levelSilvia Sirotti, Lene Terslev, Emilio Filippucci, et al.
Nature|August 16, 2023
Interferon-ε is a tumour suppressor and restricts ovarian cancerZoe R C Marks, Nicole K Campbell, Niamh E Mangan, et al.
RMD Open|February 6, 2025
OMERACT GCA phantom project: validation of a 3D-printed ultrasound training phantom for diagnosis of giant cell arteritisTobias Schremmer, Christian Dejaco, Florian Recker, et al.
Pageof 67

Showing results (631-640 of 661) with videos related to

Sort By:
Pageof 67
Nature Communications|May 28, 2020
CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancerElaine Sanij, Katherine M Hannan, Jiachen Xuan, et al.
American Journal of Hypertension|November 16, 2019
Self-monitoring of Blood Pressure in Patients With Hypertension-Related Multi-morbidity: Systematic Review and Individual Patient Data Meta-analysisJ P Sheppard, K L Tucker, W J Davison, et al.
Plos Medicine|September 20, 2017
Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysisKatherine L Tucker, James P Sheppard, Richard Stevens, et al.
Genome Biology|January 22, 2025
MaveDB 2024: a curated community database with over seven million variant effects from multiplexed functional assaysAlan F Rubin, Jeremy Stone, Aisha Haley Bianchi, et al.
Nature Communications|September 30, 2018
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaOlga Kondrashova, Monique Topp, Ksenija Nesic, et al.
The Journal of Rheumatology|March 4, 2014
Updating the OMERACT filter: implications for imaging and soluble biomarkersMaria-Antonietta D'Agostino, Maarten Boers, John Kirwan, et al.
British Journal of Cancer|July 8, 2026
Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trialKatrin M Sjoquist, Alexander Dobrovic, Kristy P Robledo, et al.
The Lancet. Rheumatology|January 22, 2024
Development and validation of an OMERACT ultrasound scoring system for the extent of calcium pyrophosphate crystal deposition at the joint level and patient levelSilvia Sirotti, Lene Terslev, Emilio Filippucci, et al.
Nature|August 16, 2023
Interferon-ε is a tumour suppressor and restricts ovarian cancerZoe R C Marks, Nicole K Campbell, Niamh E Mangan, et al.
RMD Open|February 6, 2025
OMERACT GCA phantom project: validation of a 3D-printed ultrasound training phantom for diagnosis of giant cell arteritisTobias Schremmer, Christian Dejaco, Florian Recker, et al.
Pageof 67